SUBSCRIBE
SUBSCRIBE

Phase I

Drug Development
The Day In Review: Pozen, Inc. Inks Pain Deal With AstraZeneca PLC
August 3, 2006
 · 
1 min read
Drug Development
Biotech Firm Will Test Bird Flu Vaccine On Local Residents
June 12, 2006
 · 
1 min read
Drug Development
Drug “Blocks The Spread Of HIV”
June 8, 2006
 · 
1 min read
Drug Development
TeGenero AG’s Drugs Trial “Followed Protocols”
April 5, 2006
 · 
1 min read
Drug Development
Two More Drug Trial Men Sent Home
March 31, 2006
 · 
1 min read
Drug Development
New Male Contraceptive Clears Hurdle
March 30, 2006
 · 
1 min read
Drug Development
First Clinical Trial Of Gene Therapy For Muscular Dystrophy Now Under Way
March 29, 2006
 · 
1 min read
Drug Development
Researchers Reverse Juvenile Diabetes In Animal Model; Clinical Trial FDA Approved
March 28, 2006
 · 
1 min read
Drug Development
PAREXEL International Managed Trial Goes Horribly Wrong
March 15, 2006
 · 
1 min read
Drug Development
Researchers To Begin Brain Stem Cell Trial
March 10, 2006
 · 
1 min read
Load More
PRESS RELEASES
Press Releases
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
January 19, 2026
 · 
3 min read
Press Releases
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
January 19, 2026
 · 
3 min read
Press Releases
OrsoBio Announces Nature Medicine Publication Establishing Clinical and Mechanistic Validation of First-in-Class LXR Inverse Agonist TLC-2716 for the Treatment of Serious Metabolic Diseases
January 16, 2026
 · 
4 min read
Press Releases
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
January 16, 2026
 · 
8 min read
Press Releases
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 16, 2026
 · 
7 min read
Press Releases
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
January 16, 2026
 · 
4 min read
Press Releases
Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease
January 15, 2026
 · 
2 min read
Press Releases
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
January 14, 2026
 · 
10 min read
Press Releases
Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile
January 13, 2026
 · 
6 min read
Press Releases
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
January 13, 2026
 · 
4 min read
Press Releases
Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
January 13, 2026
 · 
5 min read
Press Releases
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
January 13, 2026
 · 
4 min read
Press Releases
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
January 13, 2026
 · 
9 min read
Press Releases
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
January 13, 2026
 · 
9 min read
Press Releases
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
January 13, 2026
 · 
7 min read
Press Releases
Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome
January 12, 2026
 · 
3 min read
Press Releases
Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors
January 12, 2026
 · 
1 min read
Press Releases
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
January 12, 2026
 · 
5 min read
Press Releases
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
January 12, 2026
 · 
5 min read
Press Releases
Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi
January 12, 2026
 · 
4 min read
Load More